Home › Trials › NCT05318547
Clinical trial No longer in our active list Interventional Ages 18 and up Women only

Assessing women's preferences for postpartum blood clot prevention

Official title: Assessing Women's Preferences for Postpartum Thromboprophylaxis: the PREFER-PostPartum

Run by Fondation Hôpital Saint-Joseph · NCT05318547 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is trying to find out what women who have recently given birth prefer when it comes to preventing blood clots during the postpartum period.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment52 (estimated)
SponsorFondation Hôpital Saint-Joseph
Academic / other
Locations1 site (Paris)
Trial IDNCT05318547 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are women aged 18 and older who are either pregnant or within 7 days postpartum and fluent in French.

Probably not a fit

Patients who have experienced fetal or neonatal death or are under legal guardianship may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates women's preferences regarding thromboprophylaxis during the postpartum period to prevent venous thromboembolism (VTE). It focuses on women who are either pregnant or have recently given birth, assessing their risk factors for VTE and their willingness to use low-molecular-weight heparin as a preventive measure. The study employs techniques such as standard-gamble and time trade-off to gauge preferences and inform clinical decision-making. By understanding these preferences, the study aims to enhance patient-centered care in postpartum thromboprophylaxis.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective prevention strategies for postpartum VTE, improving maternal health outcomes.

How similar studies have gone: While there is existing research on thromboprophylaxis, this study's focus on women's preferences in the postpartum context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Women aged ≥18 years
* Ongoing pregnancy or in the early postpartum period (within 7 days of delivery)
* Participants may be with or without prior VTE or major bleeding, and with or without previous/current use of postpartum TPX.
* Fluency in French
* Women are able and willing to give free, informed and written consent

Exclusion Criteria:

* Fetal or neonatal death, in order not to bother women during their mourning.
* Women under tutorship or curatorship
* Women deprived of liberty
* Women under court protection There will be no further exclusion criteria, to maximize the external validity of the study.

Where it's running

  • Groupe Hospitalier Paris Saint-Joseph
    Paris, France     Recruiting

Study contacts

  • Principal investigator: Justine P Hugon Rodin, MD — Fondation Hôpital Saint-Joseph
  • Study coordinator: Justine Hugon Rodin, MD
  • Email: jhugon@ghpsj.fr
  • Phone: 144123934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Pregnancy 920Fondation Hôpital Saint-Joseph 18
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.